EVOK - Evoke Pharma announces positive findings from second GIMOTI market research study

Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.The study aimed to gather further market insights on perception of GIMOTI in the GI community. In May 2021, Evoke’s commercialization partner, EVERSANA, conducted the GIMOTI Awareness, Trial, Usage ((ATU)) Study. The study objectives were to understand the current gastroparesis treatment landscape and to evaluate physicians’ perceptions of GIMOTI following recent brand marketing efforts. Key findings are as follows: Continued increase in intent to prescribe GIMOTI with 81% of all respondents intend to prescribe GIMOTI in the future.Targeted gastroenterologists (GIs) report greater GIMOTI usage across first, second and third lines of treatment from the December 2020 study, with the most significant increase as a third-line treatment option from 16% to 24%.The percentage of targeted GIs reporting high awareness of GIMOTI (scoring a 4 or 5 out of 5) has increased from 21% in December 2020 to

For further details see:

Evoke Pharma announces positive findings from second GIMOTI market research study